Investors

In 2H, 2017, TAXIS will raise as much as $5M in convertible preferred debt funding to further expand and characterize the Efflux Pump Inhibitor platform, advance the MreB discovery program and complete FIH study of our lead gram-positive, QIDP-designated drug candidate, TXA709 in 2018.